Letters were sent to the CEOs of AbbVie (ABBV), Boehringer Ingelheim, Bristol Myers Squibb (BMY), Novartis (NVS), Gilead Sciences (GILD), EMD Serono, Pfizer (PFE), Novo Nordisk (NVO), AstraZeneca (AZN), Amgen (AMGN), Genentech (RHHBY), Johnson & Johnson (JNJ), GSK (GSK), Merck (MRK), Regeneron (REGN), Sanofi (SNY) and Eli Lilly (LLY), according to posts made by President Trump to his Truth Social account.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Upadacitinib Study Completion: Market Implications and Insights
- AbbVie and Genmab’s Phase 3 Trial of Epcoritamab: A Potential Game-Changer for DLBCL Treatment
- AbbVie’s Promising New Study on ABBV-453 for Multiple Myeloma
- AbbVie Advances in Psoriatic Arthritis Treatment: A New Phase 2 Study Update
- AbbVie’s Phase 3 Study on Pediatric Atopic Dermatitis: A Potential Game-Changer?